| neurotoxic effects |
phenotype |
3 |
2 |
neurotoxic effects of alcohol, neurotoxicity |
| neurotoxicity |
phenotype |
8 |
6 |
neurotoxic, neurotoxicity |
| neurotransmitter release |
phenotype |
4 |
3 |
|
| neurotransmitters |
drug |
4 |
3 |
chemical messengers |
| neurotrophin |
drug |
4 |
3 |
neurotrophic factors, neurotrophins |
| neutral |
phenotype |
4 |
1 |
Neutral stimulus, neutral condition |
| neutral condition |
phenotype |
3 |
3 |
Neutral stimulus, neutral |
| never smokers |
phenotype |
15 |
4 |
controls, never, never smoker group, non-smoker, non-smokers, unexposed group |
| New England Biolabs |
drug |
4 |
— |
NEB |
| New South Wales Brain Tissue Resource Centre |
cohort |
3 |
2 |
NSW Brain Tissue Resource Centre, NSWBTRC |
| New Zealand |
cohort |
6 |
3 |
NZ |
| next-generation sequencing data |
drug |
3 |
1 |
NGS data |
| NFBC 1966 |
cohort |
2 |
2 |
|
| NFIA |
gene |
2 |
1 |
NGFIA, Nuclear factor I A, Nuclear factor I/A |
| NFKB1 |
gene |
11 |
6 |
NF-kB, NF-kappaB1, NF-κB, NF-κB p50, NF-κB signaling, NFκB, p50, p50 homodimer, p50 subunit |
| NFKBIA |
gene |
2 |
2 |
IκBα |
| NF-κB |
gene |
19 |
10 |
NF-kB, NF-kB family, NF-kappaB, NF-κB, NF-κB isoforms, NF-κB signaling, NF-κB system, NFKB, NFkB, NFκB, NF‑kB, NF‑κB, Nuclear factor kappa B, Nuclear factor kappa-light-chain-enhancer of activated B cells, nuclear factor B, nuclear factor kappa B |
| NFκB |
gene |
6 |
3 |
NF-kappaB, NF-κB, NFKB, NFKB1, NFKB2 |
| Ngn2 |
gene |
6 |
5 |
NEUROG2, NEUROGENIN 2, NEUROGENIN2, NGN2, NGN2-iN, Neurogenin 2, Ngn2, endogenous NGN2, exogenous NGN2, hNGN2, human NGN2, mNgn2, mouse Ngn2, neurogenin 2 |
| NHGRI-EBI GWAS catalog |
cohort |
11 |
5 |
GWAS catalog |
